{"id":58911,"date":"2026-03-06T13:12:03","date_gmt":"2026-03-06T05:12:03","guid":{"rendered":"https:\/\/flcube.com\/?p=58911"},"modified":"2026-03-06T13:12:04","modified_gmt":"2026-03-06T05:12:04","slug":"hutchmed-reports-548-5-million-2025-revenue-fruzaqla-drives-26-growth-amid-china-market-headwinds","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58911","title":{"rendered":"HutchMed Reports $548.5\u202fMillion 2025 Revenue \u2013 FRUZAQLA Drives 26% Growth Amid China Market Headwinds"},"content":{"rendered":"\n

HutchMed (China) Ltd<\/strong> (NASDAQ: HCM<\/a>, HKG: 0013<\/a>) announced 2025 fiscal year results<\/strong>, recording $548.5\u202fmillion<\/strong> in consolidated total revenue, down 13% year\u2011over\u2011year<\/strong>. Despite the decline, key products delivered 5% growth<\/strong> to $524.7\u202fmillion<\/strong>, with FRUZAQLA<\/strong> (surufatinib) expanding 26%<\/strong> globally on Takeda’s commercialization strength, marking the company’s third consecutive profitable year<\/strong>.<\/p>\n\n\n\n

Revenue Performance Summary<\/h2>\n\n\n\n
Segment<\/th>2025 Revenue<\/th>Change (YOY)<\/th>Key Drivers<\/th><\/tr><\/thead>
Total Revenue<\/strong><\/td>$548.5\u202fM<\/td>\u201313%<\/strong><\/td>Absence of 2024 Takeda milestone; China pricing pressure<\/td><\/tr>
Product Sales<\/strong><\/td>$524.7\u202fM<\/td>+5%<\/strong><\/td>FRUZAQLA global expansion; H2 China recovery<\/td><\/tr>
Oncology Product Revenue<\/strong><\/td>$214.4\u202fM<\/td>\u201321%<\/strong><\/td>$20\u202fM 2024 milestone non\u2011recurring; NRDL pricing<\/td><\/tr>
Other Oncology\/Immunology<\/strong><\/td>$71.1\u202fM<\/td>\u2014<\/td>Milestones, licensing, R&D services<\/td><\/tr>
Other Business<\/strong><\/td>$263.0\u202fM<\/td>Flat<\/strong><\/td>Prescription drug distribution steady<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product\u2011Level Performance<\/h2>\n\n\n\n
Product<\/th>Market<\/th>2025 Sales<\/th>Change<\/th>Strategic Notes<\/th><\/tr><\/thead>
FRUZAQLA<\/strong> (surufatinib)<\/td>Global (Takeda)<\/td>$366.2\u202fM<\/td>+26%<\/strong><\/td>38 countries approved; 15+ launches in 2025 including Portugal, Belgium, South Korea, Mexico<\/td><\/tr>
Elunate<\/strong> (surufatinib)<\/td>China<\/td>$100.1\u202fM<\/td>\u201313%<\/strong><\/td>H2 rebound +33% vs. H1; NRDL pricing impact annualized<\/td><\/tr>
Orpathys<\/strong> (savolitinib)<\/td>China<\/td>\u2014<\/td>\u2014<\/td>3rd lung cancer indication approved; $11\u202fM milestone from AstraZeneca<\/td><\/tr>
Sulanda<\/strong><\/td>China<\/td>\u2014<\/td>\u2014<\/td>Neuroendocrine tumor franchise stable<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Regional Dynamics<\/h2>\n\n\n\n
Region<\/th>Trend<\/th>Commentary<\/th><\/tr><\/thead>
International (Takeda\u2011led)<\/strong><\/td>Strong growth<\/td>FRUZAQLA launches in Europe, Asia, Americas accelerating; regulatory momentum in 38 markets<\/td><\/tr>
China (HutchMed\u2011led)<\/strong><\/td>H2 inflection<\/td>Oncology product revenue +23% H2 vs. H1; Elunate volume recovery offsetting price cuts<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Pipeline & Visibility Catalysts<\/h2>\n\n\n\n
Asset<\/th>Status<\/th>Revenue Impact<\/th><\/tr><\/thead>
Sovleplenib<\/strong><\/td>Under regulatory review<\/td>Potential 2026 launch for primary ITP<\/td><\/tr>
Fruquintinib<\/strong><\/td>Under regulatory review<\/td>Additional indication expansion<\/td><\/tr>
FRUZAQLA<\/strong><\/td>Continued global rollouts<\/td>10+ additional markets targeted for 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n